Boston Scientific Corporation
BSXMedical Devices
$41.98−1.66%As of Oct 30vs prior close
- Market cap
- $60.8B
- P/E (TTM)
- 16.9×
- P/E (FY1)
- 13.0×
- From 52W high
- −60.01%
- EPS (LTM)
- $2.47
- Revenue (LTM)
- $21B
- Net margin
- 17.50%
Nomior Score
46
Anchored CompounderBottom 42% of the scored universe
Growth36
Quality79
Value74
Momentum0
Resilience54
Growth
+10.18%revenue a year over 9 fiscal years
YE16 $8.4BLTM $21B
Connections
Revenue to profitQ2 YE26
17% of revenue became net profit, up 1 pt on a year.
Latest resultsthird quarter 2026
- Revenue
- $5.138 billion
- Net income
- $582 million
Third quarter net sales rose modestly from the prior year, led by neuromodulation and cardiovascular, while urology and Asia-Pacific declined. GAAP net income and adjusted EPS both fell compared with the prior year period. The company raised its full-year sales growth and adjusted EPS outlook but expects fourth quarter net sales to decline.
Who owns it
7funds, 5 tracked portfolios